Psychedelic Therapy
Clinical use of psychedelics in therapeutic settings, covering psilocybin-assisted therapy, ketamine clinics, MDMA protocols, legal access, and emerging research.
A New Chapter in Mental Health Treatment
Psychedelic-assisted therapy refers to the supervised use of psychedelic substances within a structured therapeutic framework. Unlike conventional psychiatric medications taken daily, psychedelic therapy typically involves one to three substance sessions, each preceded and followed by extensive talk therapy. The model combines the pharmacological effects of the substance with the relational and psychological work of therapy, treating them as inseparable.
Current Landscape
Ketamine-assisted therapy is the most widely available form, offered in clinics across the United States and several other countries. Psilocybin-assisted therapy has shown promising results in clinical trials for treatment-resistant depression, end-of-life anxiety, and addiction, and is approved or in advanced regulatory review in several jurisdictions. MDMA-assisted therapy for PTSD completed Phase 3 trials, though its regulatory path has faced setbacks. Research into LSD, ayahuasca, and other compounds continues to expand.
Access and Considerations
Access remains uneven. Ketamine clinics can be expensive and are rarely covered by insurance. Psilocybin therapy is available in limited jurisdictions (Oregon and parts of Australia, for example) and through clinical trials. Underground and ceremonial use continues to fill gaps that the legal system has not yet addressed. Choosing a qualified therapist or guide, understanding contraindications, and having realistic expectations about outcomes are all important considerations for anyone exploring this path.